This study evaluates and aims to optimize inhalation treatment with nebulized liposomal amphotericin B in patients with chronic pulmonary aspergillosis. The primary objective is to assess the pulmonary deposition and intrapulmonary distribution of liposomal amphotericin B after nebulization, using technetium-99m-labeled liposomal amphotericin B and SPECT/CT imaging. The study also aims to generate data to inform optimization of inhalation treatment design. Participants will receive two different doses of nebulized liposomal amphotericin B (12 mg and 24 mg) on separate study days. After each administration, participants will undergo SPECT/CT imaging to assess pulmonary deposition. Blood samples will be collected on both study days and after study treatment to evaluate safety and measure systemic amphotericin B concentrations. Participants will also perform spirometry using a handheld device and complete a treatment satisfaction questionnaire on both study days.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The amount of AmBisome deposited in the lungs measured through single-photon emission computed tomography (SPECT/CT).
Timeframe: Measured at day 1 (study day 1) and at dat 14 (study day 2) after nebulisation
The amount of AmBisome in the lungs compared to the blood concentrations to understand drug absorption and distribution.
Timeframe: Measured at day 1 (study day 1) and at dat 14 (study day 2) after nebulisation
The most appropriate dose of nebulised AmBisome based on pulmonary deposition and pharmacokinetics
Timeframe: Measured at day 1 (study day 1) and at dat 14 (study day 2) after nebulisation